Nivolumab improves overall survival in patients with advanced kidney cancer: Results from the CheckMate 025 trial

The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress on Saturday and published simultaneously in the New England Journal of Medicine.

Read the whole article on Science Daily

More from Science Daily